22.6 C
New York
Saturday, June 13, 2026

Tag: LLP

FLINT Announces Transformational Recapitalization

CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FLINT Corp. ("FLINT" or the "Company") (TSX: FLNT) is pleased to announce a proposed recapitalization transaction (the "Recapitalization") that will significantly reduce the Company's debt and annual interest costs, simplify its capital structure and improve liquidity. The Recapitalization is the result of an extensive review process conducted by the Company's board of directors (the "Board"), which culminated in FLINT entering into a definitive recapitalization support agreement (the "Support Agreement") with its largest shareholder and primary lender, Canso Investment Counsel Ltd., in its capacity as portfolio manager for and on behalf of certain accounts that it manages ("Canso"). The Recapitalization is intended to preserve value for the Company's shareholders and better position FLINT to execute on future growth opportunities.

Etoiles Capital Group Co., Ltd Announces Pricing of US$5.6 million Initial Public Offering

HONG KONG, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Etoiles Capital Group Co., Ltd (Nasdaq: EFTY), a Hong Kong-headquartered financial services firm, today priced its initial public offering (the “Offering”) of 1,400,000 Class A ordinary shares at $4.00 per share. The Class A ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on August 8, 2025 under the ticker symbol “EFTY.”

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.).

JPMorgan ETFs (Ireland) ICAV: Dividend Declaration

DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) --

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Valeura Energy Inc.: Second Quarter 2025 Results

SINGAPORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) reports its unaudited financial and operating results for the three and six month periods ended June 30, 2025.

Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability of its IMPACT Phase 2b MASH Trial

Smilegate to Publish Absurd Ventures’ AAA Open-World Game Set in the A BETTER PARADISE Universe

Smilegate expands partnership with former GTA creative director Dan Houser for global AAA publishingNew game set in A Better Paradise universe in development, funded...

퍼시픽 제너럴, 미국 패스트 캐주얼 브랜드 NAYA에 투자

퍼시픽 제너럴, 미국 패스트 캐주얼 브랜드 NAYA에 투자

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform

Consistent with Manulife's strategy to increase earnings from its highest potential businessesComvest is a rapidly growing, middle market private credit managerAlignment creates a comprehensive...

Shareholders who lost money in shares of Lineage, Inc. (NASDAQ: LINE) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is September 30th
Lead Plaintiff Deadline is September 30th

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLLP